Stock Updates

How has Celgene Corporation:(NASDAQ:CELG) performed recently?

Celgene Corporation (NASDAQ: CELG) is a large market cap stock with a market cap of 86126.37. It is in the Biotechnology industry and sector Healthcare, with a current P/E of 53.83, a forward P/E of 15.84 and EPS of 2.07. At a stock price of 111.46 (0.18%) it has a dividend yield of *TBA.

EPS growth for the last five years have been 15.70%, more recently this last year it has grown by -18.80%. The next year growth is going to be about 23.30% and more long-term 22.03% after five years. EPS growth quarter over quarter is 15.00%. Sales growth for the past five years have been 20.60% and sales growth quarter over quarter is 20.70%.

For performance, Celgene Corporation the past week has seen a gain of 3.55%. For the last month performance for Celgene Corporation is 14.37%. While the last quarter is 2.99% and half year, 14.45%. Finally for the year, performance is -15.80%.

The 52-week high for Celgene Corporation, is at -18.28%, and for the 52-week low it comes to a value of 19.88%. The 20-day simple moving average is 8.17% and 4.35% for the 200-day simple moving average.

Volatility for the week is at 2.12%, and for the month it is 2.24%. Celgene Corporation, has a target price of 135.82.

In terms of debt, long term debt/equity is 2.81, and for total debt/equity Celgene Corporation has 0. The gross margin is 95.60%, while operating margin is 24.50%, the profit margin is 17.40%. The current ratio is 4.6 and the quick ratio is 4.3.

Insider ownership is at 0.20%, with instituitional ownership at 80.60%. Celgene Corporation has a payout ratio of 0.00%. With the total shares outstanding coming to 774.1. The shares float is 772.42, with the float short at 1.08%, with short ratio coming to 1.9.

In terms of returns, the return on assets see Celgene Corporation, get 6.90%, with its returns on investment at 8.90%. Return on equity is 29.70%. So will the investors see the target price of 135.82, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.


About the author

Tony Dabbs

Leave a Comment